Develop and commercialize pharmaceutical products for chronic conditions. Utilize patented BioErodible MucoAdhesive (BEMA) drug-delivery technology. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 6.8× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 51% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 28% a year on average.
There is $114.3M in the vault; even if every debt were paid off, $55.5M would remain.
The price action doesn’t yet back an upward turn. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.